Cytek Biosciences Inc
NASDAQ:CTKB
Cytek Biosciences Inc
NASDAQ:CTKB
Price:
4.01
USD
0.25%
Market Closed
Market Cap:
$512.7m
Relative Value
The Relative Value of one
CTKB
stock under the Base Case scenario is
4.1
USD.
Compared to the current market price of 4.01 USD,
Cytek Biosciences Inc
is
Undervalued by 2%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CTKB
Relative Value
Base Case
4.1
USD
Undervaluation 2%
Multiples Across Competitors
CTKB Competitors Multiples
Cytek Biosciences Inc Competitors
Cytek Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
515.5m USD | 2.6 | -7.7 | -7.8 | -6.3 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
949.8B USD | 332.5 | 3 937.7 | 1 128.4 | 2 172.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 3.9 | 26.1 | 18.4 | 24.7 | |
| US |
|
Danaher Corp
NYSE:DHR
|
132.4B USD | 5.4 | 36.6 | 18.7 | 27.2 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | 30.1 | 39.4 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.2B CHF | 5.1 | 35 | 26.1 | 26.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
262.9B CNY | 5.9 | 17.4 | 17.4 | 17.4 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.5B USD | 4.5 | 24.5 | 19.2 | 23 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.9B USD | 1.7 | 20.6 | 11.6 | 17.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
28.1B USD | 8.9 | 43.7 | 28.2 | 35.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
23.9B USD | 5.9 | 27.5 | 20.5 | 22.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
